Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for LifeStance Health (LFST) over the last 6 years, with Q3 2025 value amounting to -$2.0 million.

  • LifeStance Health's Cash from Financing Activities rose 14.81% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.1 million, marking a year-over-year decrease of 17256.11%. This contributed to the annual value of -$9.9 million for FY2024, which is 12097.33% down from last year.
  • Latest data reveals that LifeStance Health reported Cash from Financing Activities of -$2.0 million as of Q3 2025, which was up 14.81% from -$2.0 million recorded in Q2 2025.
  • In the past 5 years, LifeStance Health's Cash from Financing Activities ranged from a high of $30.8 million in Q4 2023 and a low of -$15.2 million during Q4 2021
  • In the last 5 years, LifeStance Health's Cash from Financing Activities had a median value of -$1.8 million in 2023 and averaged $4.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 18349.05% in 2022, then plummeted by 31032.5% in 2025.
  • Over the past 5 years, LifeStance Health's Cash from Financing Activities (Quarter) stood at -$15.2 million in 2021, then surged by 183.49% to $12.7 million in 2022, then surged by 143.53% to $30.8 million in 2023, then tumbled by 113.16% to -$4.1 million in 2024, then skyrocketed by 50.18% to -$2.0 million in 2025.
  • Its last three reported values are -$2.0 million in Q3 2025, -$2.0 million for Q2 2025, and -$10.0 million during Q1 2025.